Application of V-type ATPase inhibitor Verucopeptin in the treatment of radiation enteritis
CN117679419BActive Publication Date: 2026-06-26INST OF RADIATION MEDICINE CHINESE ACADEMY OF MEDICAL SCI
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- INST OF RADIATION MEDICINE CHINESE ACADEMY OF MEDICAL SCI
- Filing Date
- 2023-11-24
- Publication Date
- 2026-06-26
AI Technical Summary
Technical Problem
There are few existing drugs for treating radiation enteritis, and most of them can only play an anti-inflammatory and antibacterial role, but cannot fundamentally treat radiation-induced intestinal damage, and have poor specificity.
Method used
Verucopeptin, a V-type ATPase inhibitor, is used to treat radiation enteritis by targeting the ATP6V1G subunit of v-ATPase and strongly inhibiting v-ATPase activity. It is administered via intravenous injection.
Benefits of technology
Verucopeptin significantly reduced irradiation-induced intestinal damage, improved the intestinal microenvironment, promoted small intestinal tissue repair, increased mouse survival rate, and reduced the intestinal damage index.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN117679419B_ABST
Abstract
The application provides an application of a V-type ATPase inhibitor, verucopeptin, in treating radiation enteritis. The application mainly discloses that verucopeptin has a protective and therapeutic effect on mice with radiation-induced intestinal injury. The main performances are as follows: improving the survival rate of irradiated mice, improving the weight loss of mice, reducing the intestinal injury index and the level of active oxygen in the intestinal tract of mice after irradiation, and promoting the proliferation of small intestinal cells and the growth recovery of small intestinal villi.
Need to check novelty before this filing date? Find Prior Art